This program includes research and development of microbial strains, bioprocesses scaling, drug manufacturing, and production development.
Lallemand Health Solutions (Blagnac, France) is branding the suite of services that it offers for contract development and manufacturing operations (CDMO) for microbiome ingredients. The company has launched a program called Expert’Biome CDMO by Lallemand, officially spanning services such as research and development of microbial strains, bioprocesses scaling, drug manufacturing, and production development.
The company calls this a strategic move that will strengthen its position in the microbiome market. “Expert’Biome leverages 90 years of know-how, from research and development to pilot-scale production and commercial manufacturing for microorganisms, and uses cutting-edge technologies and innovative scientific approaches to pioneer next-generation strains,” stated Jérôme Panes, president and general manager of Lallemand Health Solutions, in a press release.
The new Expert’Biome division is led by head of business development Laurie Rey, who holds a PhD in molecular biology. Rey noted, “The microbiome is taking on new significance, as evidenced by increased research and development and commercial success.Between 2021 and 2023, there has been a 24% increase in ongoing development trials worldwide, along with an 18% increase in countries with products in development targeting the microbiome. Over the past two years, several regulatory approvals have paved the way for next-generation microbiome strains as potential drugs to improve well-being in various health areas.”